Non-addictive analgesic sustained-release drug delivery system and preparation method thereof
A non-addictive analgesic sustained-release drug delivery system, comprising: (1) a narcotic analgesic drug having a concentration of 1 mg/ml-160 mg/ml, the drug being selected from a group consisting of: a local analgesic drug, and the combination of the local analgesic drug and a nonsteroidal analgesic drug and/or an opioid analgesic drug; (2) a drug menstruum in a proportion of 1%-75% (v/v), the menstruum being selected from a group consisting of benzyl alcohol, ethanol, benzyl benzoate, ethyl lactate, and tetrahydrofurfuryl polyethylene glycol ether; and (3) a drug sustained-release formulation having a proportion of 25%-99% (v/v), the sustained-release formulation being selected from a group consisting of natural vegetable oil, synthetic lipid, artificially improved half-natural lipid and derivative thereof. Also disclosed are a preparation process and use of the sustained-release drug delivery system.
1. A non-addictive sustained-release drug delivery system comprising:
i) 12-50 mg/ml (w/v) of an anesthetic analgesic comprising a local anesthetic or a combination of a local anesthetic and at least one of parecoxib or dezocine;
ii) 10%-40% (v/v) of a drug menstruum comprising benzyl alcohol and/or benzyl benzoate, or a combination of ethanol together with benzyl alcohol and/or benzyl benzoate; and
iii) 60%-90% (v/v) of a drug sustained-release agent comprising soybean oil and/or castor oil,
wherein the local anesthetic is selected from the group consisting of ropivacaine free base or a methanesulfonate, hydrochloride, citrate, sulfate, lactate, succinate, fumarate, glutamate, ethylsulfonate, benzenesulfonate, salicylate, or maleate salt thereof, and
wherein the non-addictive sustained-release drug delivery system is oily, homogenous, and configured for injection.
2. The non-addictive sustained-release drug delivery system of claim 1 , wherein the anesthetic analgesic is ropivacaine free base.